Hyperlipidemia with HDL-C <
Conditions
Interventions
Pitavastatin for 6 months
Sponsors
Kanazawa Medical University Diabetology and Endocrinology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Outpatients, 20 years old or above, regardless of sex. 2. HDL-C<50mg/dL 3.Patients who receive the treatment with statin (excluded to pitavastatin), or patients who do not reach the target value of management in high LDL cholesterolemia 4. Patients who are able to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients corresponding to the contraindication of pitavastatin 1)Known hypersensitivity to product components 2)Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels(Severe liver damage: AST, ALT >=500IU/L) 3)Co-administration with cyclosporine. 4)Pregnant women, patients who may become pregnant, or nursing mothers 2.Patients who wish to become pregnant 3.Patients who are considerd unsuitable for inclusion by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in HDL-C | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in lipid profile (TC, TG, LDL-C, non HDL-C). Investigation of factors associated with Changes in HDL-C. | — |
Countries
Japan
Contacts
Public ContactYuka Kuroshima
Kanazawa Medical University Diabetology and Endocrinology
Outcome results
None listed